{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T22:34:36Z","timestamp":1723242876597},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T00:00:00Z","timestamp":1454889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T00:00:00Z","timestamp":1454889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1038\/bmt.2015.348","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T15:11:23Z","timestamp":1454944283000},"page":"654-662","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas"],"prefix":"10.1038","volume":"51","author":[{"given":"F","family":"Heinzelmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D W","family":"Beelen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Engelhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Bunjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Holler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Baurmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Haubitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Ottinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,8]]},"reference":[{"key":"BFbmt2015348_CR1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin's Lymphoma Classification Project A","year":"1997","unstructured":"The Non-Hodgkin's Lymphoma Classification Project A. Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. Blood 1997; 89: 3909\u20133918.","journal-title":"Blood"},{"key":"BFbmt2015348_CR2","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725\u20133732.","journal-title":"Blood"},{"key":"BFbmt2015348_CR3","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008; 26: 4579\u20134586.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR4","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336\u20134342.","journal-title":"Blood"},{"key":"BFbmt2015348_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441\u2013449.","journal-title":"N Engl J Med"},{"key":"BFbmt2015348_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 2013; 122: 981\u2013987.","journal-title":"Blood"},{"key":"BFbmt2015348_CR7","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","volume":"26","author":"C Sebban","year":"2008","unstructured":"Sebban C, Brice P, Delarue R, Haioun C, Souleau B, Mounier N et al. Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. J Clin Oncol 2008; 26: 3614\u20133620.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR8","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1002\/cncr.28243","volume":"119","author":"AM Evens","year":"2013","unstructured":"Evens AM, Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS et al. Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer 2013; 119: 3662\u20133671.","journal-title":"Cancer"},{"key":"BFbmt2015348_CR9","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3324\/haematol.2012.069583","volume":"98","author":"S Montoto","year":"2013","unstructured":"Montoto S, Matthews J, Greaves P, Lillington D, Anderson D, Gribben JG et al. Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse. Haematologica 2013; 98: 620\u2013625.","journal-title":"Haematologica"},{"key":"BFbmt2015348_CR10","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1200\/JCO.2012.46.9718","volume":"31","author":"GA Salles","year":"2013","unstructured":"Salles GA, Morschhauser F, Solal-Celigny P, Thieblemont C, Lamy T, Tilly H et al. Obinutuzumab (GA101) in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2920\u20132926.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2013-01-481341","volume":"122","author":"J Radford","year":"2013","unstructured":"Radford J, Davies A, Cartron G, Morschhauser F, Salles G, Marcus R et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed\/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 2013; 122: 1137\u20131143.","journal-title":"Blood"},{"key":"BFbmt2015348_CR12","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1200\/JCO.2010.32.1844","volume":"29","author":"N Fowler","year":"2011","unstructured":"Fowler N, Kahl BS, Lee P, Matous JV, Cashen AF, Jacobs SA et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol 2011; 29: 3389\u20133395.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","volume":"15","author":"NH Fowler","year":"2014","unstructured":"Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15: 1311\u20131318.","journal-title":"Lancet Oncol"},{"key":"BFbmt2015348_CR14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008\u20131018.","journal-title":"N Engl J Med"},{"key":"BFbmt2015348_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88\u201394.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR16","doi-asserted-by":"crossref","unstructured":"Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF et al. The BCL-2-specific BH3-Mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: interim results of a phase I study. Blood (Annu Meet Abstr) 2012; 120: abstract 304.","DOI":"10.1182\/blood.V120.21.304.304"},{"key":"BFbmt2015348_CR17","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","volume":"67","author":"CA Ramos","year":"2016","unstructured":"Ramos CA, Heslop HE, Brenner MK . CAR-T Cell Therapy for Lymphoma. Ann Rev Med 2016; 67: 165\u2013183.","journal-title":"Ann Rev Med"},{"key":"BFbmt2015348_CR18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood.V77.3.649.649","volume":"77","author":"RJ Jones","year":"1991","unstructured":"Jones RJ, Ambinder RF, Piantadosi S, Santos GW . Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649\u2013653.","journal-title":"Blood"},{"key":"BFbmt2015348_CR19","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/cncr.23375","volume":"112","author":"M Sorror","year":"2008","unstructured":"Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992\u20132001.","journal-title":"Cancer"},{"key":"BFbmt2015348_CR20","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1200\/JCO.1995.13.5.1096","volume":"13","author":"KW van Besien","year":"1995","unstructured":"van Besien KW, Khouri IF, Giralt SA, McCarthy P, Mehra R, Andersson BS et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 1995; 13: 1096\u20131102.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR21","first-page":"1832","volume":"92","author":"K van Besien","year":"1998","unstructured":"van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832\u20131836.","journal-title":"Blood"},{"key":"BFbmt2015348_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1053-4296(05)80028-1","volume":"5","author":"JM Cosset","year":"1995","unstructured":"Cosset JM, Socie G, Girinsky T, Dubray B, Fourquet A, Gluckman E . Radiobiological and Clinical Bases for Total Body Irradiation in the Leukemias and Lymphomas. Semin Radiat Oncol 1995; 5: 301\u2013315.","journal-title":"Semin Radiat Oncol"},{"key":"BFbmt2015348_CR23","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","volume":"102","author":"K van Besien","year":"2003","unstructured":"van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521\u20133529.","journal-title":"Blood"},{"key":"BFbmt2015348_CR24","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","volume":"98","author":"IF Khouri","year":"2001","unstructured":"Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595\u20133599.","journal-title":"Blood"},{"key":"BFbmt2015348_CR25","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1182\/blood-2003-05-1406","volume":"103","author":"RD Faulkner","year":"2004","unstructured":"Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103: 428\u2013434.","journal-title":"Blood"},{"key":"BFbmt2015348_CR26","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","volume":"104","author":"E Morris","year":"2004","unstructured":"Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865\u20133871.","journal-title":"Blood"},{"key":"BFbmt2015348_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/sj.bmt.1705027","volume":"36","author":"E Kusumi","year":"2005","unstructured":"Kusumi E, Kami M, Kanda Y, Murashige N, Kishi Y, Suzuki R et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005; 36: 205\u2013213.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015348_CR28","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","volume":"119","author":"IF Khouri","year":"2012","unstructured":"Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 2012; 119: 6373\u20136378.","journal-title":"Blood"},{"key":"BFbmt2015348_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3324\/haematol.10924","volume":"92","author":"S Vigouroux","year":"2007","unstructured":"Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007; 92: 627\u2013634.","journal-title":"Haematologica"},{"key":"BFbmt2015348_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","volume":"26","author":"AR Rezvani","year":"2008","unstructured":"Rezvani AR, Storer B, Maris M, Sorror ML, Agura E, Maziarz RT et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 211\u2013217.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","volume":"14","author":"P Hari","year":"2008","unstructured":"Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236\u2013245.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015348_CR32","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204\u2013217.","journal-title":"Am J Med"},{"key":"BFbmt2015348_CR33","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628\u20131633.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015348_CR34","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR35","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1182\/blood.V92.10.3515","volume":"92","author":"EW Petersdorf","year":"1998","unstructured":"Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998; 92: 3515\u20133520.","journal-title":"Blood"},{"key":"BFbmt2015348_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"PF Jason","year":"1999","unstructured":"Jason PF, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"BFbmt2015348_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2307\/1402659","volume":"43","author":"NE Breslow","year":"1975","unstructured":"Breslow NE . Analysis of survival data under the proportional hazards model. Int Stat Rev 1975; 43: 45\u201357.","journal-title":"Int Stat Rev"},{"key":"BFbmt2015348_CR38","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","volume":"95","author":"JL Pinana","year":"2010","unstructured":"Pinana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Diez-Martin JL et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95: 1176\u20131182.","journal-title":"Haematologica"},{"key":"BFbmt2015348_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s12185-013-1430-9","volume":"98","author":"Y Ito","year":"2013","unstructured":"Ito Y, Miyamoto T, Kamimura T, Takase K, Henzan H, Sugio Y et al. Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. Int J Hematol 2013; 98: 463\u2013471.","journal-title":"Int J Hematol"},{"key":"BFbmt2015348_CR40","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","volume":"31","author":"AJ Peniket","year":"2003","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667\u2013678.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015348_CR41","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","volume":"17","author":"T Shea","year":"2011","unstructured":"Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17: 1395\u20131403.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015348_CR42","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","volume":"21","author":"RL Haas","year":"2003","unstructured":"Haas RL, Poortmans P, de Jong D, Aleman BM, Dewit LG, Verheij M et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol 2003; 21: 2474\u20132480.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","volume":"51","author":"T Girinsky","year":"2001","unstructured":"Girinsky T, Guillot-Vals D, Koscielny S, Cosset JM, Ganem G, Carde P et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 2001; 51: 148\u2013155.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbmt2015348_CR44","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1038\/sj.onc.1204318","volume":"20","author":"C Belka","year":"2001","unstructured":"Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 2001; 20: 2190\u20132196.","journal-title":"Oncogene"},{"key":"BFbmt2015348_CR45","doi-asserted-by":"publisher","first-page":"5043","DOI":"10.1038\/sj.onc.1204659","volume":"20","author":"RU Janicke","year":"2001","unstructured":"Janicke RU, Engels IH, Dunkern T, Kaina B, Schulze-Osthoff K, Porter AG . Ionizing radiation but not anticancer drugs causes cell cycle arrest and failure to activate the mitochondrial death pathway in MCF-7 breast carcinoma cells. Oncogene 2001; 20: 5043\u20135053.","journal-title":"Oncogene"},{"key":"BFbmt2015348_CR46","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/sj.bjc.6690585","volume":"80","author":"MA Sheard","year":"1999","unstructured":"Sheard MA, Krammer PH, Zaloudik J . Fractionated gamma-irradiation renders tumour cells more responsive to apoptotic signals through CD95. Br J Cancer 1999; 80: 1689\u20131696.","journal-title":"Br J Cancer"},{"key":"BFbmt2015348_CR47","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.bbmt.2011.11.026","volume":"18","author":"GA Hale","year":"2012","unstructured":"Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ et al. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. Biol Blood Marrow Transplant 2012; 18: 1036\u20131043.e1.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015348_CR48","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1093\/annonc\/mdu440","volume":"25","author":"I El-Najjar","year":"2014","unstructured":"El-Najjar I, Boumendil A, Luan JJ, Bouabdallah R, Thomson K, Mohty M et al. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party. Ann Oncol 2014; 25: 2224\u20132229.","journal-title":"Ann Oncol"},{"key":"BFbmt2015348_CR49","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood.V89.6.2189","volume":"89","author":"M Rocha","year":"1997","unstructured":"Rocha M, Umansky V, Lee KH, Hacker HJ, Benner A, Schirrmacher V . Differences between graft-versus-leukemia and graft-versus-host reactivity. Blood 1997; 89: 2189\u20132202.","journal-title":"Blood"},{"key":"BFbmt2015348_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev.immunol.25.022106.141606","volume":"25","author":"LA Welniak","year":"2007","unstructured":"Welniak LA, Blazar BR, Murphy WJ . Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25: 139\u2013170.","journal-title":"Annu Rev Immunol"},{"key":"BFbmt2015348_CR51","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481\u20133485.","journal-title":"Blood"},{"key":"BFbmt2015348_CR52","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558\u2013565.","journal-title":"Blood"},{"key":"BFbmt2015348_CR53","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179\u20134187.","journal-title":"Blood"},{"key":"BFbmt2015348_CR54","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1365-2141.2009.07905.x","volume":"147","author":"I Avivi","year":"2009","unstructured":"Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H, Mufti GJ et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2009; 147: 719\u2013728.","journal-title":"Br J Haematol"},{"key":"BFbmt2015348_CR55","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013; 122: 2943\u20132964.","journal-title":"Blood"},{"key":"BFbmt2015348_CR56","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/bmt.2013.73","volume":"48","author":"HW Auner","year":"2013","unstructured":"Auner HW, Szydlo R, van Biezen A, Iacobelli S, Gahrton G, Milpied N et al. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013; 48: 1395\u20131400.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015348_CR57","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood.V98.7.2043","volume":"98","author":"C Kollman","year":"2001","unstructured":"Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043\u20132051.","journal-title":"Blood"},{"key":"BFbmt2015348_CR58","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/sj.bmt.1705195","volume":"37","author":"E Carreras","year":"2006","unstructured":"Carreras E, Jimenez M, Gomez-Garcia V, de la Camara R, Martin C, Martinez F et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2006; 37: 33\u201340.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2015348_CR59","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","volume":"117","author":"ME Flowers","year":"2011","unstructured":"Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214\u20133219.","journal-title":"Blood"},{"key":"BFbmt2015348_CR60","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/leu.2012.210","volume":"27","author":"N Kroger","year":"2013","unstructured":"Kroger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A et al. Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia 2013; 27: 604\u2013609.","journal-title":"Leukemia"},{"key":"BFbmt2015348_CR61","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/sj.leu.2404822","volume":"21","author":"P Corradini","year":"2007","unstructured":"Corradini P, Dodero A, Farina L, Fanin R, Patriarca F, Miceli R et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007; 21: 2316\u20132323.","journal-title":"Leukemia"},{"key":"BFbmt2015348_CR62","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","volume":"28","author":"KJ Thomson","year":"2010","unstructured":"Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010; 28: 3695\u20133700.","journal-title":"J Clin Oncol"},{"key":"BFbmt2015348_CR63","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.bbmt.2011.12.581","volume":"18","author":"CO Freytes","year":"2012","unstructured":"Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L et al. Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. Biol Blood Marrow Transplant 2012; 18: 1255\u20131264.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2015348_CR64","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/asheducation.V2012.1.417.3798521","volume":"2012","author":"GG Laport","year":"2012","unstructured":"Laport GG . Changing role of stem cell transplantation in follicular lymphoma. Hematology Am Soc Hematol Educ Program 2012; 2012: 417\u2013425.","journal-title":"Hematology Am Soc Hematol Educ Program"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt2015348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015348","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt2015348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:11:04Z","timestamp":1648062664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2015348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,8]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["BFbmt2015348"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2015.348","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,8]]},"assertion":[{"value":"12 May 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}